Ticker Details
4D Molecular Therapeutics, Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$460.09M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.61 | 3.59%
Avg Daily Range (30 D):	$0.28 | 3.31%
Avg Daily Range (90 D):	$0.36 | 3.70%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.65M
Avg Daily Volume (90 D):	.77M

Trade Size
Avg Trade Size (Sh.):	76
Avg Trade Size (Sh.) (30 D):	73
Avg Trade Size (Sh.) (90 D):	74

Institutional Trades
Total Institutional Trades:	1,151
Avg Institutional Trade:	$1.8M
Avg Institutional Trade (30 D):	$.78M
Avg Institutional Trade (90 D):	$1.13M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.78M
Avg Closing Trade (30 D):	$.77M
Avg Closing Trade (90 D):	$1.15M
Avg Closing Volume:	104.37K

News

Feb 19, 2026 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: Na

Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics

Oct 31, 2025 @ 3:02 AM 4DMT Announces Exclusive License Agreement with Ot... Source: 4D Molecular Therapeutics

Sep 11, 2025 @ 10:00 AM GenVivo Strengthens Oncology Leadership with Appoi... Source: Genvivo, Inc.

Aug 11, 2025 @ 12:16 PM 4dMT Revenue Jumps 200 Percent in Q2 Source: Jesterai

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-3.75	$-1.01	$-.98
Diluted EPS	$-3.75	$-1.01	$-.98
Revenue	$.12M	$.09M	$.02M
Gross Profit
Net Income / Loss	$-209.18M	$-56.88M	$-54.66M
Operating Income / Loss	$-230.38M	$-61.19M	$-59.46M
Cost of Revenue
Net Cash Flow	$-138.98M	$-28.6M	$-72.18M
PE Ratio